StemCyte
StemCyte is a privately held U.S. cord blood bank and regenerative therapeutics company founded in 1997, operating private and public cord blood banking alongside FDA-licensed REGENECYTE® cell therapy, serving expectant parents, academic researchers, and clinical trial sponsors across 40 countries.
- Company typePrivate
- Founded1997
- HeadquartersCovina, United States
- Headcount501–1,000
- GTM typeB2B and B2C
- OfferingServices
What StemCyte does
StemCyte, Inc. is a privately held U.S. cord blood banking and regenerative therapeutics company founded in 1997 and headquartered in Baldwin Park, California. The company operates a dual private-and-public cord blood bank under a single cGMP, FDA-licensed (US License 2280), FACT- and AABB-accredited platform. Its consumer-facing banking service offers annual, 18-year prepaid, and lifetime cord blood and cord tissue storage plans sold direct-to-consumer to U.S. expectant parents through a five-language website and an inside-sales call center, with add-on modules including MaxCell® premium processing, Newborn Genetic Analysis (a 258-gene NGS panel), Public Bank Access tiers, HLA typing, and a bundled LifeSaver Guarantee. Published lifetime MSRP is $5,625, positioned as the lowest among the five major U.S. private cord blood banks.
StemCyte generates revenue through a mix of one-time private-banking enrollment fees, recurring storage annuities, transaction-fee add-ons, B2B sales of cord-derived cellular materials (cord blood, Wharton's Jelly MSCs, CD34+ HSPCs, MSC exosomes) to academic institutions and biotech developers, and long-tail licensing/royalty upside from REGENECYTE® (HPC, Cord Blood), an FDA-licensed allogeneic hematopoietic progenitor cell therapy with RMAT designation for Long COVID. The Biologics division is supported by a sponsored clinical pipeline across Long COVID, acute ischemic stroke, cerebral palsy, and a collaborative IMPAACT P1107 HIV cure study, plus an FDA-cleared Expanded Access Program for Long COVID.
Since 1997, StemCyte has delivered more than 2,300 cord blood units to over 325 transplant centers in 40 countries. Its customer base spans U.S. consumers (long-tail, one-decision-per-birth), B2B research buyers at institutions such as City of Hope, USC, CHLA, and UCLA, clinical trial sponsors, and — as of November 2025 — insurance-linked distribution partners beginning with Taishin Life in Taiwan. The company is privately held, with Diamond Biofund having invested US$6.35 million as part of a broader capital raise exceeding US$25 million announced in November 2023, alongside plans for a Taiwan Innovation Board listing.
StemCyte firmographics
Firmographics- Name
- StemCyte
- Legal name
- StemCyte, Inc.
- Website
- https://stemcyte.com
- Company type
- Private
- Founded year
- 1997
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- StemCyte is a privately held U.S. cord blood bank and regenerative therapeutics company founded in 1997, operating private and public cord blood banking alongside FDA-licensed REGENECYTE® cell therapy, serving expectant parents, academic researchers, and clinical trial sponsors across 40 countries.
- Ownership category
- akta.pro rank
StemCyte industry classification
Industry- Product category
- Cord Blood Banking Services
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Blood and Organ Banks (621991), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Cell & Tissue Banking (biobanking, cord blood/tissue) (HLAAAGAE)
- akta.pro secondary industries
- Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE), Stem Cell–Based Regenerative Therapies (HLAAAGAA), Cardiovascular & Vascular Regeneration (vascular grafts, angiogenesis) (HLAAAGAJ)
Keywords
Where StemCyte is headquartered
LocationHeadquarters
- HQ city
- Covina
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
StemCyte business model
Business model- GTM type
- B2B and B2C
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Supply Chain
Revenue model
- Private cord blood banking plans: One-time enrollment revenue for cord blood and cord tissue storage plans (annual, 18-year prepaid, and lifetime options), plus optional split-pay over 6 or 12 months. The published lifetime cord blood plan is $5,625 MSRP — positioned as the lowest among the five major US private banks. Stored inventory scales with the number of enrolled families and forms a recurring annual storage annuity.
- Advanced Protection add-ons: One-time transaction-fee add-ons layered onto any private banking plan: MaxCell® premium processing, Newborn Genetic Analysis ($399), Public Bank Access ($299, covers the child) and Public Bank Access+ ($699, extends to parents). Each represents an incremental transaction with no recurring obligation.
- LifeSaver Guarantee and warranty economics: LifeSaver Guarantee is bundled free with every plan but creates contingent liability and a potential $50,000 payout obligation plus replacement unit from the public bank in the rare event of engraftment failure — a financial-services-style risk pool that is part of the value proposition and pricing logic.
- Biologics — cellular materials and research supply: B2B revenue from selling cord-derived cellular materials (whole cord blood units, cord tissue/Wharton's Jelly, MSCs, CD34+ HSPCs ≥90% purity, MSC exosomes, a cord blood cellular therapy product) as research-use and co-development starting materials to academic institutions, biotech developers, and clinical-trial sponsors. Includes custom specifications and pooled-donor formats on request.
- Clinical development and licensing (REGENECYTE®): Long-term value capture from REGENECYTE®, an FDA-licensed allogeneic HPC, Cord Blood therapy with RMAT designation for Long COVID, an FDA-cleared Expanded Access Program (2026), and three sponsored clinical trials (Long COVID Phase IIa, acute ischemic stroke Phase II, cerebral palsy Phase II). Includes data licensing, partnership, and future commercialization revenue tied to the cell therapy pipeline.
- Professional services — HLA typing and post-sale add-ons: One-time services such as HLA typing on privately banked units (so the unit's profile can be searched against registries if a family member needs treatment), Newborn Genetic Analysis reporting, and post-18-year continuing storage at $200/year or prepaid lifetime lock-in.
- Insurance-linked distribution partnerships: Revenue share / partnership economics from insurance-linked public cord blood access products (e.g., Public Bank Matching Protection Service launched in Taiwan with Taishin Life), with planned US and other-region rollouts supported by AI-driven matching.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Pay-as-you-go | Cord blood banking plans (annual, 18-year prepaid, lifetime) |
| One time/ perpetual license | Pay-as-you-go | Public Bank Access (PBA) — $299 one-time add-on |
| One time/ perpetual license | Pay-as-you-go | Public Bank Access+ (PBA+) — $699 one-time add-on |
| One time/ perpetual license | Pay-as-you-go | Newborn Genetic Analysis (NGA) — $399 one-time add-on |
| One time/ perpetual license | Pay-as-you-go | MaxCell® premium cord blood processing add-on |
| Subscription | Pay-as-you-go | Cord blood + cord tissue bundle |
Go-to-market motion4 records
Distribution channels5 records
Marketing channels8 records
StemCyte product offering
Product offeringCore offering
StemCyte operates one of the only dual private and public cord blood banks in the U.S., selling family-directed cord blood and cord tissue banking plans directly to expectant parents, layered with Advanced Protection add-ons (MaxCell® premium processing, Newborn Genetic Analysis, Public Bank Access, HLA typing, LifeSaver Guarantee). Through its StemCyte Biologics division it develops REGENECYTE® — an FDA-licensed (US License 2280) allogeneic HPC, Cord Blood therapy — and supplies cord-derived cellular materials (cord blood, MSCs, CD34+ HSPCs, MSC exosomes) to academic institutions, biotech developers, and clinical-trial sponsors.
Product overview
StemCyte, Inc. operates a two-arm platform-plus-modules architecture: a Cord Blood Banking consumer service (both private family banking and public registry donation) supported by add-on modules such as Cord Tissue Banking, MaxCell® premium processing, HLA Typing, Newborn Genetic Analysis (NGA), Public Bank Access / Public Bank Access+, and the LifeSaver Guarantee; and a separate StemCyte Biologics division built around the FDA-licensed core therapy REGENECYTE® (HPC, Cord Blood, US License 2280), with its clinical pipeline (Long COVID, Acute Ischemic Stroke, Cerebral Palsy, and the IMPAACT P1107 HIV cure collaboration), an Expanded Access Program for Long COVID, and a B2B Cellular Materials catalog supplying fresh/frozen cord blood, cord tissue, MSCs, CD34+ HSPCs, and MSC exosomes to research and clinical-trial sponsors. The two arms share StemCyte's FACT- and AABB-accredited public cord blood bank and FDA-registered cGMP facility in Baldwin Park, California, and are coordinated through AI-driven donor matching and an FDA-licensed manufacturing/release-testing platform.
Differentiator
Problem solved
Functional benefit
Brands
- StemCyte Biologics: Clinical development arm of StemCyte, Inc., advancing cord blood-derived cell therapies including REGENECYTE® and StemCyte-sponsored clinical trials in Long COVID, ischemic stroke, and cerebral palsy.
- REGENECYTE®
- MaxCell®
- Public Bank Access (PBA)
- LifeSaver Guarantee
Quantifiable outcome
- 85% fatigue resolution in REGENECYTE® Phase IIa Long COVID trial vs. 20% in placebo group (p < 0.01)
- +4 more outcomes
Companies that use StemCyte
Customer profileNamed customers6 records
Segments5 records
Ideal customer profiles3 records
StemCyte technology and API
TechnologyAPI detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature7 records
StemCyte partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered flagship, core and minor.
- Taishin LifeflagshipStemCyte International launched its Public Bank Matching Protection Service in Taiwan in partnership with Taishin Life, connecting insurance coverage to public cord blood resources and REGENECYTE® therapy. The collaboration is supported by StemCyte's AI-driven matching and manufacturing advancements and is described as the first insurance-linked public cord blood access product in Taiwan, with plans for further partnerships in the U.S. and other regions.
- City of HopecoreCity of Hope is one of the academic institutions listed by StemCyte Biologics as a customer / supporter that purchases cord-derived cellular materials for research and translational programs. Dr. Christine L. (Hematologist, City of Hope) provides a customer testimonial endorsing StemCyte. StemCyte's Chief Medical Officer Joseph Rosenthal, MD is also a Professor Emeritus at City of Hope.
- USC (University of Southern California)minorListed by StemCyte Biologics among the academic research institutions it supports with cord-derived cellular materials (cord blood, cord tissue, MSCs, CD34+ HSPCs, exosomes) for research and IND-enabling programs.
- CHLA (Children's Hospital Los Angeles)minorListed by StemCyte Biologics among the academic research institutions it supports with cord-derived cellular materials for pediatric research and translational programs.
- UCLAminorListed by StemCyte Biologics among the academic research institutions it supports with cord-derived cellular materials for academic and translational research.
- IMPAACT Network (P1107 trial)coreStemCyte contributes cord blood units (including the CCR5Δ32/Δ32 homozygous unit) to the IMPAACT P1107 observational trial (NCT02140944) toward an HIV cure. The collaboration contributed to the 'New York Patient' case — the first possible HIV cure in a woman — published in Cell in 2023.
- NervGen PharmaminorNervGen Pharma is named in the 2026 Spinal Cord Injury pipeline alongside StemCyte as a key company developing emerging regenerative therapies and devices for SCI. The article references partnerships aimed at advancing regenerative treatments for spinal cord injury.
- VA Office of Research and DevelopmentminorNamed in the 2026 Spinal Cord Injury pipeline alongside StemCyte as a key organization developing regenerative treatments and devices for SCI.
- Kessler Foundation / Kessler InstituteminorNamed in the 2026 Spinal Cord Injury pipeline alongside StemCyte as a key organization in SCI clinical research.
Scale indicators12 records
Recent moves7 records
Expansion highlights6 records
StemCyte competitors and assessment
Company assessmentRegional players
- China Cord Blood Corporation: China Cord Blood Corporation operates the largest cord blood banking network in China, a comparable private/public cord blood banking business model to StemCyte but focused exclusively on the Greater China market.
Emerging players
- Mesoblast Limited: Mesoblast is a clinical-stage cell therapy company developing allogeneic MSC-based therapies (remestemcel-L, rexlemestrocel-L) for inflammatory and degenerative diseases, directly overlapping with StemCyte Biologics' cord-tissue MSC and regenerative-medicine pipeline.
- Celularity Inc. Celularity develops placenta-derived cellular therapies including allogeneic NK and MSC candidates, overlapping with StemCyte Biologics' REGENECYTE® and MSC exosome programs in regenerative medicine and cell therapy indications.
Direct peers
- Americord Registry: Americord is one of the five major U.S. private cord blood banks named in StemCyte's competitive comparison, offering cord blood, cord tissue, and placental tissue banking plans to U.S. expectant parents.
- Cryo-Cell International: Cryo-Cell is one of StemCyte's two named FACT-accredited private U.S. cord blood bank peers, offering private and public cord blood banking plans, menstrual stem cell banking, and is a similarly long-tenured (founded 1989) U.S. competitor with comparable product structure.
- Cord Blood Registry (CBR) by Generate Life Sciences: CBR is the largest U.S. private cord blood bank and one of the five major competitors StemCyte benchmarks against; it offers comparable private banking plans and is a direct substitute at the point of sale to expectant parents.
- New York Blood Center (National Cord Blood Program): NYBC operates one of the largest public cord blood banks in the U.S. and is a direct competitor to StemCyte's public bank; supplies donor units to NMDP-network transplant centers in overlapping therapeutic indications.
- ViaCord (Revvity): ViaCord is a long-established U.S. private cord blood bank, owned by Revvity (formerly PerkinElmer), and one of the five major U.S. private banks named in StemCyte's head-to-head comparison; competes directly on price, processing technology, and HLA-typing services.
Broad incumbents
- Lonza Cell & Gene Therapies: Lonza is a global CDMO leader in cell and gene therapy manufacturing, including cGMP cord blood-derived and allogeneic cell therapy production; comparable to StemCyte's cGMP manufacturing platform from a buyer/competitor perspective in the Biologics B2B supply chain.
- Hemacord (New York Blood Center / FDA HPC, Cord Blood): Hemacord was the first FDA-licensed HPC, Cord Blood product (2011) and is a direct regulatory peer to StemCyte's REGENECYTE® in the FDA-licensed allogeneic cord blood therapy category; provides a competitive benchmark for market access and pricing.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
StemCyte social profiles
Digital presenceStemCyte compliance and trust
Trust signalCompliance9 records
StemCyte financial estimates
Financial estimateRevenue estimate
Valuation estimate
StemCyte leadership team
Management profileNumber of profiles
Profiles4 records
StemCyte subsidiaries and ownership
Company hierarchySubsidiaries1 record
StemCyte funding detail
Funding detailFunding overview
Funding rounds3 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
StemCyte M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about StemCyte
What does StemCyte do?
StemCyte operates one of the only dual private and public cord blood banks in the U.S., selling family-directed cord blood and cord tissue banking plans directly to expectant parents, layered with Advanced Protection add-ons (MaxCell® premium processing, Newborn Genetic Analysis, Public Bank Access, HLA typing, LifeSaver Guarantee). Through its StemCyte Biologics division it develops REGENECYTE® — an FDA-licensed (US License 2280) allogeneic HPC, Cord Blood therapy — and supplies cord-derived cellular materials (cord blood, MSCs, CD34+ HSPCs, MSC exosomes) to academic institutions, biotech developers, and clinical-trial sponsors.
Is StemCyte a public or private company?
StemCyte is a private company. It is classified as venture growth investor backed and is currently operating.
When was StemCyte founded?
StemCyte was founded in 1997. It employs 501 to 1,000 people.
Where is StemCyte based?
StemCyte is headquartered in Covina, United States, in the North America region.
How does StemCyte make money?
Seven revenue lines are on record. Private cord blood banking plans are the primary driver. The others are advanced Protection add-ons, lifeSaver Guarantee and warranty economics, biologics — cellular materials and research supply, clinical development and licensing (REGENECYTE®), professional services — HLA typing and post-sale add-ons and insurance-linked distribution partnerships.
Who are StemCyte's main competitors?
China Cord Blood Corporation is listed as a regional player. Emerging players are Mesoblast Limited and Celularity Inc.. Direct peers are Americord Registry, Cryo-Cell International, Cord Blood Registry (CBR) by Generate Life Sciences, New York Blood Center (National Cord Blood Program) and ViaCord (Revvity). Broad incumbents are Lonza Cell & Gene Therapies and Hemacord (New York Blood Center / FDA HPC, Cord Blood).
Does StemCyte have an API?
No public API is recorded for StemCyte.
What industry is StemCyte in?
StemCyte's product category is Cord Blood Banking Services. Its primary akta.pro industry code is HLAAAGAE, Cell & Tissue Banking (biobanking, cord blood/tissue), with a secondary code of HLAAABAE, Stem Cell Therapies (MSC/iPSC/HSC-derived). Its NAICS code is 325414 and its SIC code is 2836.